These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15942701)

  • 41. Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.
    Zhou Y; Yu L; Li J; Zhang L; Tong Y; Kan B
    Int J Antimicrob Agents; 2013 Jul; 42(1):72-5. PubMed ID: 23643392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
    Pan XS; Yague G; Fisher LM
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T; Tanaka M; Yamaguchi A; Sato K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
    Rozen DE; McGee L; Levin BR; Klugman KP
    Antimicrob Agents Chemother; 2007 Feb; 51(2):412-6. PubMed ID: 17116668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.
    Millichap JJ; Pestova E; Siddiqui F; Noskin GA; Peterson LR
    J Clin Microbiol; 2001 Jul; 39(7):2719-21. PubMed ID: 11427605
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutations in the gyrB, parC, and parE genes of quinolone-resistant isolates and mutants of Edwardsiella tarda.
    Kim MS; Jun LJ; Shin SB; Park MA; Jung SH; Kim K; Moon KH; Jeong HD
    J Microbiol Biotechnol; 2010 Dec; 20(12):1735-43. PubMed ID: 21193831
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fluoroquinolone resistance in atypical pneumococci and oral streptococci: evidence of horizontal gene transfer of fluoroquinolone resistance determinants from Streptococcus pneumoniae.
    Ip M; Chau SS; Chi F; Tang J; Chan PK
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2690-700. PubMed ID: 17548487
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular characterization of genes encoding the quinolone resistance determining regions of Malaysian Streptococcus pneumoniae strains.
    Kumari N; Subramaniam G; Navaratnam P; Sekaran SD
    Indian J Med Microbiol; 2008; 26(2):148-50. PubMed ID: 18445951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
    Rafii F; Park M; Novak JS
    Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fluoroquinolone resistance in Streptococcus pneumoniae isolates in Germany from 2004-2005 to 2014-2015.
    Schmitz J; van der Linden M; Al-Lahham A; Levina N; Pletz MW; Imöhl M
    Int J Med Microbiol; 2017 Jun; 307(4-5):216-222. PubMed ID: 28506425
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association between proline-requiring auxotype and fluoroquinolone resistance in Neisseria gonorrhoeae isolated in Japan.
    Tsunoe H; Tanaka M; Mochida O; Nakayama H; Kanayama A; Saika T; Kobayashi I; Naito S
    J Infect Chemother; 2001 Dec; 7(4):218-23. PubMed ID: 11810587
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel gyrase mutations and characterization of ciprofloxacin-resistant clinical strains of Enterococcus faecalis isolated in Poland.
    Piekarska K; Gierczyński R; Ławrynowicz-Paciorek M; Kochman M; Jagielski M
    Pol J Microbiol; 2008; 57(2):121-4. PubMed ID: 18646399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones.
    Ho PL; Yam WC; Que TL; Tsang DN; Seto WH; Ng TK; Ng WS
    J Antimicrob Chemother; 2001 May; 47(5):655-8. PubMed ID: 11328779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [MALDI-ToF mass-spectrometry in analysis of genetically determined resistance of Streptococcus pneumoniae to fluoroquinolones].
    Malakhova MV; Vereshchagin VA; Il'ina EN; Govorun VM; Filimonova OIu; Grudinina SA; Sidorenko SV
    Antibiot Khimioter; 2007; 52(1-2):10-7. PubMed ID: 18461803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro antibacterial activities of new fluoroquinolones against clinical isolates of haemophilus influenzae with ciprofloxacin-resistance-associated alterations in GyrA and ParC.
    Yoshizumi S; Takahashi Y; Watanabe Y; Okezaki E; Ishii Y; Tateda K
    Chemotherapy; 2004 Dec; 50(6):265-75. PubMed ID: 15608441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro assessment of the further potential for development of fluoroquinolone resistance in Neisseria meningitidis.
    Shultz TR; White PA; Tapsall JW
    Antimicrob Agents Chemother; 2005 May; 49(5):1753-60. PubMed ID: 15855492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
    Adam HJ; Schurek KN; Nichol KA; Hoban CJ; Baudry TJ; Laing NM; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2007 Jan; 51(1):198-207. PubMed ID: 17088485
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.
    Roychoudhury S; Twinem TL; Makin KM; McIntosh EJ; Ledoussal B; Catrenich CE
    J Antimicrob Chemother; 2001 Jul; 48(1):29-36. PubMed ID: 11418510
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
    Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Rice CL; Doern GV
    Clin Infect Dis; 2005 Jan; 40(2):225-35. PubMed ID: 15655739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.